WCN26-3774 A bispecific antibody targeting Gd-IgA1 and TfR1 enhances Gd-IgA1 degradation and mitigates IgA nephropathy

Read full text Summarise with VIRAT
Authors: Mengting Fang, Xueqing Yu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is characterized by glomerular mesangial deposition of IgA1 immune complexes. Galactose-deficient IgA1 (Gd-IgA1) is a key pathogenic driver of the disease. Reducing its levels represents a promising therapeutic strategy.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Monoclonal and Polyclonal Antibodies Research Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105812–105812
Publication date
25 March 2026
Language
EN